|1.||O'Byrne, Paul M: 21 articles (01/2015 - 07/2002)|
|2.||Szefler, Stanley J: 18 articles (01/2013 - 04/2002)|
|3.||Selroos, Olof: 15 articles (01/2014 - 01/2002)|
|4.||Sandborn, William J: 14 articles (11/2015 - 01/2002)|
|5.||Greinwald, Roland: 13 articles (01/2016 - 07/2003)|
|6.||Parasuraman, Bhash: 13 articles (09/2010 - 03/2003)|
|7.||Pedersen, Søren: 13 articles (12/2009 - 06/2002)|
|8.||Uryniak, Tom: 12 articles (12/2015 - 05/2006)|
|9.||Barnes, P J: 11 articles (10/2012 - 01/2000)|
|10.||Lubet, Ronald A: 11 articles (12/2011 - 07/2002)|
|1.||Asthma (Bronchial Asthma)
03/01/2003 - "Clinically important (> or = 0.5 unit) improvement in Asthma Quality of Life Questionnaire overall at week 18 was demonstrated by 55% and 43% of patients in the 400/200-microg and 200/200-microg budesonide Turbuhaler groups, respectively. "
12/01/2001 - "In both randomized studies, budesonide inhalation suspension demonstrated statistically significant improvement in nighttime and daytime asthma symptom scores compared with placebo. "
02/01/2000 - "This study demonstrates that when patients with moderate asthma had reached a stable clinical condition with a high dose of budesonide, a low dose of budesonide (200 microg/d) is as effective as the standard dose (800 microg/d) in the control of symptoms and lung function over a period of several months. "
07/01/2014 - "The baseline characteristics of the budesonide group (n=33) and placebo group (n=33) were similar, but at 1 hour, 2 hour and 3 hour PEFR, respiratory rate, pulse rate, SaO2 and asthma score were significantly improved in the budesonide group compared to placebo group (p<0.01). "
01/01/2014 - "These findings show that Bifidobacterium breve M-16 V and Lactobacillus rhamnosus NutRes1 have strong anti-inflammatory properties that are comparable to budesonide and therefore may be beneficial in the treatment of chronic asthma."
|2.||Crohn Disease (Crohn's Disease)
08/01/2002 - "Budesonide is significantly more effective than placebo or 5-ASA for inducing remission of active Crohn's disease. "
11/01/1995 - "Oral treatment with controlled release budesonide 9 mg/day for 8 weeks produces clinical remission in 42 to 67% of patients with active Crohn's disease of the ileum, ileocaecal region and/or ascending colon and significantly reduces Crohn's disease activity index scores compared with baseline and placebo. "
01/01/2009 - "Therefore, budesonide is not recommended for maintenance of remission in Crohn's disease."
04/01/1997 - "The evidence presented here is that budesonide (Entocort, Astra Pharma) 9 mg/day is superior to placebo and equivalent to systemically active glucocorticosteroids in achieving disease remission in patients with active Crohn's disease, and in prolonging the recurrence time of symptomatic disease. "
02/01/1996 - "In an enteric-coated formulation budesonide is more effective than placebo in achieving and maintaining remission in patients with ileocecal Crohn's disease. "
|3.||Chronic Obstructive Pulmonary Disease (COPD)
01/01/2011 - "Intratracheal administration of BUD-SSMs 23 hours before challenge (1 mg/kg) in an asthmatic/chronic obstructive pulmonary disease rat model led to a significant reduction in inflammatory cell counts (76.94 ± 5.11) in bronchoalveolar lavage fluid compared with administration of Pulmicort Respules (25.06 ± 6.91). "
01/01/2013 - "If atopic COPD patients are treated with budesonide, they more often show remission of symptoms compared to non-atopic COPD patients who are treated with budesonide. "
05/29/1999 - "We investigated the efficacy of inhaled budesonide on decline in lung function and respiratory symptoms in a 3-year placebo-controlled study of patients with COPD. "
06/24/1999 - "In patients with mild COPD who continue smoking, the use of inhaled budesonide is associated with a small one-time improvement in lung function but does not appreciably affect the long-term progressive decline."
01/01/2013 - "The European Respiratory Society Study on Chronic Obstructive Pulmonary Disease (EUROSCOP) investigated long-term effects of budesonide; 18% of the COPD participants were atopic. "
02/01/2003 - "Budesonide is a highly effective and well tolerated treatment of collagenous colitis. "
12/01/2013 - "Oral budesonide has been proven effective in short- and long-term treatment of collagenous colitis; however, symptom relapse frequently occurs after drug withdrawal. "
01/01/2004 - "Collagenous colitis treated successfully with budesonide."
05/01/2014 - "Studies reporting that budesonide is effective for the treatment of collagenous colitis have been small and differed in efficacy measures. "
01/01/2008 - "Budesonide is effective for inducing and maintaining clinical and histological response in patients with collagenous colitis. "
11/01/1992 - "These results provide good evidence that intranasal budesonide is effective in seasonal rhinitis in children."
01/01/2012 - "In addition, compound 6b is more effective than budesonide in the murine rhinitis model. "
12/01/1988 - "This study suggests that intranasal budesonide is an effective and well-tolerated treatment for perennial rhinitis."
05/01/1988 - "The present study suggests that intranasal budesonide in the dose of 200-400 micrograms/day is also a safe treatment for prolonged treatment of perennial rhinitis."
01/01/2006 - "Intranasal Budesonide is effective and safe in alleviating the symptoms of chronic nonallergic rhinitis."
|2.||Adrenal Cortex Hormones (Corticosteroids)
|2.||Nebulizers and Vaporizers (Inhaler)
|5.||Metered Dose Inhalers (Metered Dose Inhaler)